Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised VEF Ltd in connection with a directed share issue
Mandate

Vinge has advised VEF Ltd in connection with a directed share issue

November 19, 2020 Capital Markets and Public M&A

Vinge has advised VEF Ltd, an investment company whose Swedish Depositary Receipts (“SDR”) are listed on Nasdaq First North, in connection with a directed share issue whereby VEF receives approximately SEK 522 million in issue proceeds.

The subscription price was determined to SEK 3.15 per SDR through an accelerated book building process. The share issue was directed to selected Swedish and international investors. The company intends to use the expected net proceeds from the transaction to enable potential near-term investment opportunities.

VEF Ltd is an investment company that invests in growth stage private fintech companies. VEF focuses on scale emerging markets and invests across all areas of financial services inclusive of payments, credit, mobile money and wealth advisors. VEF trades in Sweden on Nasdaq First North Growth Market under the ticker VEFL SDB.

Vinge’s team consisted of Jesper Schönbeck, Joel Wahlberg and Eléonore Friberg.

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025